Jun 05,2023

JDRF & DigiBete's Virtual Type 1 Diabetes Discovery Event - Tomorrow Evening

JDRF and DigiBete hosted a virtual event discovery about type 1 diabetes on the 6th of June focusing on ongoing education materials and type 1 diabetes. The event addressed the challenges of managing diabetes and shared ideas and lived experiences on navigating school and college. Resources aimed at helping the community manage type 1 diabetes in educational settings were also showcased.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 06,2023

Diabetes Devices Market size to hit $48 Bn by 2033

The diabetes devices market is projected to exceed $48 billion by 2033, with an expected compound annual growth rate (CAGR) of over 7% from 2023 to 2033, according to a study by Research Nester. The industry's growth is driven by the increasing number of individuals affected by diabetes globally, with diabetic complications causing a significant number of deaths worldwide. Key players in the market include Medtronic, Abbott Laboratories, Bayer, Dexcom, and Sanofi.

View Analyst & Ambassador Comments
Go to original news
Jul 17,2020

A Digital Lifestyle Program in Outpatient Treatment of Type 2 Diabetes: A Randomized Controlled Study

Lifestyle is important in type 2 diabetes mellitus (T2DM). This study’s aim was to investigate whether a healthy-lifestyle-supporting smartphone application could affect treatment outcomes at an endocrinology outpatient clinic. In addition to standard care, intervention group participants used a smartphone application to access a lifestyle program (SidekickHealth) through which they received personalized recommendations and education about healthy lifestyles. Results indicate that the SidekickHealth digital lifestyle program could potentially enhance outpatient treatment in T2DM, in terms of both glycemic control and psychological well-being but larger confirmative studies are needed.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 08,2023

Dexcom to Host Investor Day on June 23, 2023

DexCom, Inc. today announced that it will host an Investor Day on June 23rd from 2:30 PM until approximately 5:00 PM PST (5:30 PM – 8:00 PM EST). The event will include presentations from Dexcom management highlighting the company’s market opportunities, business strategy, innovation efforts, and long-term financial outlook.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Jun 05,2023 TOP STORY

Novo Nordisk enters exclusive negotiations to acquire a controlling stake in BIOCORP, to be followed by a tender offer on all remaining shares

Novo Nordisk A/S and BIOCORP Production SA announced today that Novo Nordisk has entered into exclusive negotiations for a controlling stake in BIOCORP, which would be followed by a mandatory simplified tender offer on all remaining outstanding shares in BIOCORP1 at a price of 35.00 Euros per share in cash, representing a total equity value of approximately 154 million Euros. Since 2021 the companies have been collaborating on the development and commercialisation of a Mallya add-on device for the Novo Nordisk FlexTouch pen used by people with diabetes, and during 2022 and 2023 this engagement has been expanded to the development of versions of the Mallya device for other therapy areas. Following the acquisition, Novo Nordisk would aim to preserve the agility and entrepreneurial spirit of BIOCORP, while investing further in the organization with the goal of delivering cutting edge devices and delivery solutions to improve care for people across the globe living with serious chronic diseases.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 04,2023

The Smart Insulin Pens Market is expected to cross US$ 8,750.7 Million by 2033, at a CAGR of 8.3% through the forecast period 2033 end

The global smart insulin pens market is projected to reach over US$ 8,750.7 million by 2033, with a compound annual growth rate (CAGR) of 8.3%, according to the research publisher. Factors driving the market include the increasing prevalence of diabetes, technological advancements, and new product launches.

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 07,2023 TOP STORY

Ypsomed partners with S3 Connected Health to expand its digital health offering

Ypsomed, in partnership with S3 Connected Health, is expanding its digital health solutions to enhance therapy management for patients with acute and chronic diseases, with a focus on diabetes. The collaboration aims to create an extendable platform, called Affinial, for therapy-specific digital patient solutions. The new platform offering includes a patient application, a clinical system, a Patient Support Portal (PSP portal) and analytical dashboard with real-time access to anonymized data. Alongside pre-integration of Ypsomed’s device portfolio, the platform provides a range of features around self-injection, incorporates behavioral science mechanisms to ensure high levels of engagement, and personalization of the application to users’ needs. The new product offering will be marketed through Ypsomed and will be offered to customers in collaboration with S3 Connected Health for customization to serve their specific use cases and brand.

COLLABORATION PARTNERSHIP

#r&d

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 07,2023 TOP STORY

Dario Announces Two New Full Suite Employer Contracts

DarioHealth Corp. announced today two new employer contracts for the Company's full suite of integrated solutions. The new accounts are scheduled to launch in the second half of 2023, involve an educational organization in Tennessee and a non-profit in the New York metropolitan area. Both new accounts selected Dario for the ease of a single, integrated solution to provide employees with a more holistic approach to chronic condition management and to reduce administrative burdens and cost for the employer.

PRODUCT

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 19,2018

DIABEO App Software and Telemedicine Versus Usual Follow-Up in the Treatment of Diabetic Patients: Protocol for the TELESAGE Randomized Controlled Trial

Self-management of diabetes minimizes the risk of macrovascular and microvascular complications, but understanding and/or adherence to self-management recommendations is often suboptimal. The researchers present the protocol for a new study TELESAGE, a multicenter, double-randomized, open-label, three parallel–arms study, conducted in approximately 100 centers in France, in a larger population of diabetic patients with poorly controlled basal-bolus insulin levels. DIABEO is a smartphone app used to calculate bolus insulin doses. A previous study (TELEDIAB 1) showed that the use of DIABEO was associated with a significant improvement in glycemic control in patients with poorly controlled type 1 diabetes mellitus, particularly when combined with teleconsultations with physicians. The primary objective of TELESAGE will be to investigate the effect of the DIABEO telemedicine system versus usual follow-up, with respect to improvements in the glycated hemoglobin levels of approximately 696 diabetic patients with poorly controlled basal-bolus insulin levels.

CLINICAL STUDY

#telehealth

#mobile app

View Analyst & Ambassador Comments
Go to original news
Jun 01,2023

Dexcom Announces Upcoming Conference Presentation

DexCom announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at William Blair's 43rd Annual Growth Stock Conference on Wednesday, June 7th. The live presentation is scheduled to begin at approximately 1:40 PM EST and will be concurrently webcast.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES